AZD5069 is a potent, selective reversible (time and temperature dependent) antagonist of the human CXCR2 receptor that used for caner treatment.
AZD-5069 is a potent and selective CXCR2 antagonist with potential as a therapeutic agent in inflammatory conditions.
AZD 5069 is an antagonist of chemokine receptor 2 (CXCR2; IC50 = 0.79 nM in a radioligand binding assay). It inhibits CXCL1-induced CD11b expression in and chemotaxis of isolated human neutrophils (pA2s = 6.9 and 9.1, respectively). AZD 5069 (3 and 10 μmol/kg) inhibits bronchoalveolar lavage fluid (BALF) neutrophil influx in a rat model of LPS-induced lung neutrophilia and non-allergic airway inflammation.
